ReviewMaterials today. Bio2025
Engineered metallic hybrid nanozyme for advanced inflammatory disease therapy.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Copper-Doped Prussian Blue Nanozymes With Hyaluronic Acid-Mediated Targeting Alleviate Oxidative Stress and Regulate Cholesterol Handling for Atherosclerosis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineering Catalytic Nanozymes for Antimicrobial Food Systems: Structure-Activity Relationships, Safe-by-Design Principles, and Industrial Translation.Nanomaterials (Basel, Switzerland) · 2026Review
- Cerium-doped carbon dots for multifunctional biomedical applications: enhanced heavy metal sensing, antioxidant-driven wound healing, and RAFT polymer-mediated improved gene complexation capability.Mikrochimica acta · 2026Article
- Metal-Functionalized Nanozymes in Antibacterial Wound Management: Recent Advances and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation poses significant therapeutic challenges due to the limitations of conventional treatments. Nanozymes, merging nanomaterial properties with enzymatic catalysis, offer promising alternatives for inflammation therapy. Among them, metallic nanozymes have attracted considerable attention due to their tunable physicochemical properties and multi-therapeutic potential. However, single-metal nanozymes suffer from insufficient catalytic efficiency, high therapeutic dosage requirements, and limited functionality, which severely hinder their clinical translation. Recent advances in metallic hybrid nanozymes, which integrate the advantages of different metallic elements, have enabled synergistic enhancement of catalytic performance and cascade effects, offering more effective solutions for inflammation treatment. In this review, we first systematically outline the fundamental principles, molecular mechanisms, and current therapeutic approaches for inflammation. Subsequently, we comprehensively discuss the definition, catalytic mechanisms, and rational design strategies of nanozymes, with a focus on the common synthesis methods, activity regulation mechanisms, computer-aided design strategies, and combination therapy approaches for metallic hybrid nanozymes. Furthermore, we provide an in-depth evaluation of the applications of metallic hybrid nanozymes in treating various inflammatory diseases. Finally, we critically analyze the key scientific challenges and future directions in the clinical translation of metallic hybrid nanozymes. This work provides a comprehensive framework for developing next-generation nanozyme therapeutics, bridging fundamental research and clinical applications in inflammation management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.